Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 5/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731864 | 0.89 | MAP2K4 (0.49) | MAP2K4ELANECCNB2CDK1CCNB1 | |
| SCHEMBL14764815 | 0.88 | MAP2K4 (0.51) | MAP2K4ELANECCNB2CDK1CCNB1 | |
| SCHEMBL24148970 | 0.88 | MAP2K4 (0.51) | MAP2K4ELANECCNB2CDK1CCNB1 | |
| SCHEMBL25994433 | 0.87 | MAP2K4 (0.56) | MAP2K4ELANEMAPTCKS1BSKP1 | |
| SCHEMBL24148209 | 0.86 | MAP2K4 (0.54) | MAP2K4ELANECCNB2CDK1CCNB1 | |
| SCHEMBL4006762 | 0.86 | MAP2K4 (0.58) | MAP2K4ELANEMAPTCKS1BSKP1 | |
| SCHEMBL24148625 | 0.83 | AXL (0.46) | MAP2K4CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL27788236 | 0.82 | ELANE (0.48) | ELANEMAPTPOLBKDM4EPRNP | |
| SCHEMBL4005625 | 0.82 | L3MBTL1 (0.61) | MAP2K4ELANEMAPTPOLBKMT2A | |
| SCHEMBL24148229 | 0.82 | MAP2K4 (0.45) | MAP2K4ELANECCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | MAP2K4 88/4885ELANE 4449/4885CCNB2 458/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | MAP2K4 88/4885ELANE 4449/4885CCNB2 458/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | MAP2K4 3056/4885ELANE 1923/4885CCNB2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.